The deal adds new products to Mölnlycke’s portfolio, helping healthcare professionals and patients in speeding up wound healing process and treatment of chronic wounds.

SastoMed will join Mölnlycke and will add two complementary products to the parent company’s wound care portfolio.

The first product is Granulox, a haemoglobin-based topical oxygen therapy spray that is sprayed on wounds for faster wound healing.

Studies claim that Granulox can reduce total costs of initial Diabetic foot ulcers treatment by around 60% a year.

The second product is Granudacyn, a ahypochlorous wound irrigation solution for cleaning, moistening and rinsing of acute, chronic and contaminated wounds and first and second degree burns.

These two new products will enable Mölnlycke to provide both active and passive wound healing solutions.

Mölnlycke CEO Richard Twomey said: “Today, chronic wounds, such as foot ulcers, have a higher mortality rate than both breast cancer and prostate cancer and the real burden of ulcers is not yet fully known or understood.

“Mölnlycke will now be able to offer healthcare professionals – and patients – solutions to support both active and passive healing. We can therefore offer a holistic approach to wound treatment through our portfolio.”

Presently, Granulox is available in more than 24 countries, SastoMed’s main customer base is in Germany, South East Asia and Central and Latin America.

With the acquisition, Mölnlycke is planning to expand the geographical reach of Granulox and Granudacyn through its worldwide distribution network and sales organisation.

The acquisition is expected to help Mölnlycke in expanding its presence in key growth markets across South East Asia and Central and Latin America.

SastoMed founder Michael Sander said: “We share Mölnlycke’s desire to advance healthcare around the world. Too often, patients experience slow wound healing since no appropriate therapy is available to overcome the lack of oxygen in the wound tissue.

“Now we feel it´s the right time to pass the baton to the leading company in advanced wound care, in order to make our unique products available to as many patients as possible.”